Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response by unknown
Pegylated Interferon and Ribavirin Dosing Strategies
to Enhance Sustained Virologic Response
Eric Chak & Sammy Saab
Published online: 19 June 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Hepatitis C virus (HCV) affects about 170 million
people worldwide and is the most common chronic blood
borne infection in the United States. Since the advent of blood
screening protocols in the early 1990s, injection drug use has
become the leading cause of infection. Hepatitis C can have
both hepatic and nonhepatic manifestations of infection.
Hepatic manifestations include hepatic fibrosis, cirrhosis, liver
cancer, and liver failure. The standard treatment for chronic
HCV is combination therapy with pegylated interferon-α and
ribavirin. Although pegylated interferon and ribavirin has been
used against HCV for close to a decade, advances in therapy
have centered on doses and treatment durations. There has
been increasing interest in applying on-treatment response or
viral kinetics to predict antiviral response rates and shape
therapeutic intervention. Protease inhibitors are a promising
adjuvant to combination therapy, but their efficacy and safety
are still under investigation.
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Introduction
Hepatitis C virus (HCV) infection is a worldwide public
health and medical concern. About 170 million persons are
infected worldwide, with an estimated 3 to 4 million
Americans infected [1]. Since the advent of blood screening
measures, injectable drug use has supplanted transfusion-
related HCV transmission as the leading cause of new
infections [1]. Many individuals with chronic hepatitis C
(CHC) are unaware of their infection and are diagnosed
incidentally. Indeed, the cohort of individuals infected two
or three decades ago are now seeking medical care, and
presenting with advanced liver disease [2].
CHC can lead to hepatic fibrosis, cirrhosis, hepatocellular
carcinoma, and hepatic failure. Hepatitis C is currently the
most common indication for liver transplantation in the United
States [3]. Current treatment strategies for CHC involve an
immune modulator, pegylated interferon (peginterferon)-α
and the antiviral drug, ribavirin. The mechanism of
interferon’s antiviral activity is thought to interact directly
to interferon-stimulated response elements on DNA leading
to translation of proteins that interfere with HCV replication
and have immunomodulatory actions on the innate and
adaptive immune systems [4]. Similarly, ribavirin is believed
to work via RNA viral mutagenesis [5].
Treatment using interferon-based therapy improves
patient outcomes and natural history [6, 7]. The survival
in one study was related to duration of antiviral therapy [8].
The predictors of antiviral response are stratified according
to host, viral, and on-treatment factors [9]. Unfortunately,
most of these factors are nonmodifiable. The genetic
polymorphism in the interleukin (IL) 28b gene can predict
the likelihood of achieving a sustained virologic response
(SVR). This finding highlights the important role of the
human host in dealing with the viral infection. Indeed, IL-
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28B genotype is an important predictor in achieving a
sustained viral response in patients with hepatitis C
genotype 1.
Although some guidelines have been established, dura-
tion of treatment and dosing strategies of the aforemen-
tioned drugs are still being optimized in an effort to
improve the SVR. Recent studies have demonstrated
increasing efficacy in extended therapy beyond 48 weeks
in slow interferon responders, and the use of weight-based
ribavirin. Furthermore, select patients may not require
standard treatment durations.
Epidemiology
There are six HCV genotypes, which appear to vary by
region of the world. In the United States and Western
Europe, genotype 1 is the most common, followed by
genotypes 2 and 3. Genotypes 4, 5, and 6 are generally
found in Egypt, South Africa, and Southeast Asia,
respectively. According to the most recent National Health
and Nutrition Examination survey, the prevalence of anti-
HCV antibodies in the United States is about 1.6%. The
peak prevalence was seen in those ages 40 to 49 years with
the strongest risk factor being injection drug use. However,
the survey did not include incarcerated or homeless
persons, so the true prevalence of HCV infection may
actually be much higher than reported [10].
Natural History of Infection
Although HCV accounts for about 20% of acute hepatitis in
the United States [11], it is generally not diagnosed in the
acute phase because most patients are asymptomatic.
Recent data has suggested that genetic polymorphisms
upstream of the IL28B gene may be related to the ability to
spontaneously clear the virus. Of note, patients with the
C/C genotype have been shown to have spontaneous
clearance rates of 50% to 55%, but those with the T/T
genotype only had clearance rates of 16% to 20% [12••].
The authors of this study note that the C allele is more
common in people of European than African ancestry.
Preliminary data suggest the genetic polymorphism may
also predict treatment response in patients infected with
CHC virus genotype 1 [13••].
Of patients who are acutely infected with HCV, the viral
load can be detected as early as 1 to 3 weeks and antibodies
detected between 2 and 3 months after exposure [14], and
more than 90% will have anti-HCV antibodies 3 months
after first exposure. Further, 54% to 86% of patients fail to
clear the virus by 6 months and develop a chronic hepatitis
[15]. Over time, fibrosis and then cirrhosis may develop.
Hepatocellular carcinoma (HCC) develops in about 1% to
5% of patients with CHC infection after 2 decades of
infection [14].
Indications for Treatment
According to recent guidelines from the American Associ-
ation for the Study of Liver Diseases (AASLD), any patient
who is infected with HCV should be considered a candidate
for treatment [16]. Specifically, the AASLD recommends
treating patients with compensated liver disease (total
serum bilirubin <1.5 g/dL, International Normalized Ratio
1.5, serum albumin >3.4, platelet count 75,000 mm, and no
evidence of encephalopathy or ascites). The risk and
benefits of antiviral therapy need to be considered, and
patients must be healthy enough to endure the treatment
regimen. Patients being treated should have a liver biopsy
showing evidence of chronic liver injury. Because of the
high SVR rate and the short duration of treatment, the liver
biopsy may be considered optional in patients with
genotypes 2 and 3. Contraindications to treatment include
uncontrolled major depressive illness, history of solid organ
transplant (other than liver), autoimmune hepatitis, and
severe concurrent medical diseases like heart failure,
coronary artery disease, and chronic obstructive pulmonary
disease.
Treatment Strategies
Antiviral therapy is associated with several adverse effects,
and a varied likelihood of achieving long-term viral
suppression. Thus, patients on therapy are assessed on a
regular basis to determine treatment continuation. Therapy
is discontinued in patients who do not achieve viral
milestones, because antiviral therapy is no longer considered
efficacious. The goal of therapy is to achieve a SVR, defined
as an undetectable viral load 6 months after completing
antiviral therapy.
Currently, two major milestones help predict SVR and
determine continual use of antiviral therapy. First, patients
must achieve an early virologic response (EVR), defined as
at least a 2-log drop in the viral load 12 weeks after starting
therapy [17]. If treated patients do not achieve this
milestone, SVR is unlikely to be realized, and therapy
should be discontinued. In the last several years, the clinical
impact of an EVR has been further refined. The predict-
ability of achieving SVR in those patients who develop
complete viral suppression (complete EVR [cEVR]) is
different from those who achieve a 2-log drop but
detectable virus (partial EVR [pEVR]). Higher SVR are
realized with cEVR in comparison with pEVR [18••, 19••].
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The second milestone is the viral load at week 24 of
therapy. Treatment is continued only if the viral level is
undetectable. Other definitions used to characterize
patients’ response to antiviral therapy include end-of-
treatment response (EOT), defined as an undetectable viral
level at the end of therapy. Figure 1 demonstrates viral
milestones and definitions used during HCV antiviral
treatment.
There has been increasing interest in another milestone,
the viral load 4 weeks after starting antiviral therapy (rapid
virologic response [RVR]). Patients who have an undetect-
able viral level at this time have an increased likelihood of
achieving a SVR. In fact, the likelihood of achieving a SVR
is similar: high regardless of genotype [20].
Other terms used in describing patients’ response to
antiviral therapy include null response (lack of 2-log drop
with antiviral therapy), and partial response (2-log drop in
viral load, but viral load still detectable 24 weeks after
starting therapy).
Currently Approved Doses for HCV Genotypes 1, 2, and 3
The approved doses and duration of antiviral therapy are
shown in Table 1. Patients infected with genotypes 1 and 4
require 48 weeks of treatment, whereas for those infected
with genotypes 2 and 3, 24 weeks of treatment are believed
sufficient. No large prospective study for the treatment for
genotypes 5 and 6 exists, but it seems reasonable to treat
these patients like genotypes 1 and 4 because they would be
receiving the maximum length of combination therapy
under those regimens.
Weight-based Ribavirin Therapy
Recent data from a large, multicenter, prospective trial has
suggested that weight-based ribavirin (800 mg for patients
<65 kg; 1000 mg for patients 65–85 kg; 1200 mg for
patients >85–100 kg; and 1400 mg for patients >105 but
<125 kg) is more effective than flat-dose ribavirin in
patients with genotype 1 (44.2% vs 40.5%), and safety
profiles for each group were similar [21••]. Other studies
have also suggested weight-based ribavirin dosing may be
beneficial in patients infected with genotype 2 and 3. For
instance, in patients with genotype 2 and 3, giving a lower
dose of peginterferon-α-2a (135 µg/wk compared to the
standard dose of 180 µg/wk) yielded high rates of SVR
(85%–86%) when treated with weight-based ribavirin
(11 mg/kg daily) [22••]. Other studies suggest the duration
of therapy may be shortened in patients with genotype 2
and 3 infected patients treated with full-dose peginterferon-
α when weight based ribavirin is used [23••, 24, 25••].
Duration of Therapy
Shortened Therapy for Genotypes 2 and 3
Research over the past several years has focused on
tailoring therapy based on the patient’s virologic response
to antiviral therapy. Currently, the standard duration and
ribavirin dosing is 24 weeks and 800 mg ribavirin per day.
However, several studies have demonstrated that similar
sustained viral response rates may be obtained in patients
treated for less than 24 weeks as long as certain criteria
are met: rapid viral response (RVR), weight-based
ribavirin dosing, low baseline viral load, and minimal
fibrosis [23••, 24, 25••].
In one of the largest clinical trials assessing the duration
of antiviral therapy in patients with genotype 2 and 3,
Shiffman et al. [24] showed that there was a significant
decrease in SVR when therapy was less than the approved
24 weeks as part of the multinational ACCELERATE trial.
However, weight-based ribavirin dosing was not used.
Recent data from the ACCELERATE investigators showed
that patients with HCV viral load <400,000 who achieve
RVR may be candidates for shortened therapy even while
using flat-dose ribavirin [26]. Mangia et al. [23••] showed
that patients treated with peginterferon-α-2a and weight-
based ribavirin for 12 weeks had similar rates of SVR
compared to those treated for the standard 24-week course
Fig. 1 Terms used to describe different responses to treatment for
chronic hepatitis C virus. Rapid viral response (RVR)—undetectable
viral level 4 weeks after starting antiviral therapy. Partial early viral
response (pEVR), the “slow responder”—a 2 log10 drop in viral load
that is still detectable 12 weeks after starting antiviral therapy, but the
viral load becomes undetectable by week 24. Complete early viral
response (cEVR)—detectable viral load at week 4, but undetectable
12 weeks after starting therapy. Sustained virologic response (SVR)—
viral load that is undetectable 24 weeks after completing antiviral
therapy. However, if the full treatment course is only 24 weeks, as can
be the case with genotype 2 and 3 patients, SVR is achieved at week
48 instead of week 72.
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(76% vs 77%, CI−13 to 10). Other trials found that treating
patients with peginterferon and weight-based ribavirin
showed similar rates of SVR for 14 weeks [25••] and
16 weeks [27••] of treatment compared to the standard
duration of 24 weeks. Predictors of response weight-
based ribavirin in these trials included the absence of
bridging fibrosis or cirrhosis, lower pretreatment HCV
RNA level, and lower body weight [24]. Thus, it would be
reasonable to treat genotype 2 and 3 patients possessing
these favorable characteristics for 12 to 16 weeks with
peginterferon-α and weight-based ribavirin with the expec-
tation of similar rates of SVR compared to 24 weeks of
treatment.
Shortened Therapy for Genotype 1
Similarly, in genotype 1 patients whose viral loads are
undetectable after only 4 weeks of treatment (RVR),
Zeuzem et al. [28] showed that patients with baseline
HCV RNA <600,000 IU/ml had an SVR rate similar to
controls (89% vs 85%) when treated with only 24 weeks of
combination therapy. However, these studies need to be
confirmed in the United States because of different
demographic and, potentially, IL28B allele distribution.
Thus, shortened therapy in genotype 1 patients is not
recommended at this time.
Indeed, patients who achieve a RVR have a high likelihood
of achieving SVR regardless of genotype [20, 24, 29•, 30].
However, likelihood of achieving an RVR does vary by
genotype. Patients with genotype 1 have a 16% likelihood of
achieving a RVR, compared to 60% to 70% with genotypes
2 and 3 [20, 24, 29•, 30].
Extended Therapy for Genotype 1
Slow responders who achieve the milestone of a pEVR
appear to benefit from extended therapy of 72 rather than
48 weeks. In the study by Berg et al. [19••], patients who
had a pEVR had a SVR rate of 17% if they were treated for
48 weeks and 29% if treated for 72 weeks (P=0.04). In
addition, patients who derived the most benefit from
extended therapy were those whose absolute viral level at
week 24 was less than 6,000 IU/mL. In a separate study by
Pearlman et al. [18••], extending treatment duration from
48 weeks to 72 weeks in patients with pEVR was found to
be beneficial (38% vs 18%, P=0.026). Support for
extended therapy is supported by the results of a recent
Spanish study (Table 2) [31].
Treatment with High-dose Peginterferon
The use of higher than normal doses of peginterferon is
currently under investigation and this may yield relevant
treatment options for difficult to treat populations. One
study by Buti et al. [32] randomly assigned 28 genotype 1
patients to receive three different once-weekly doses of
peginterferon-α-2b (3 µg/kg for 1 week, 1.5 µg/kg for
3 weeks, and 1.0 µg/kg for 44 weeks). The control group of
27 patients would receive low-dose peginterferon (0.5 µg/kg
for 48 weeks). Both groups also received ribavirin. The
Table 1 Standard treatment for chronic hepatitis C
Genotype Dose of peginterferon Dose of ribavirin Duration of treatment, wk
1,4 Peginteferon-α-2a, 180 µg weekly or 1000 mg (body weight <75 kg) or 1200 mg
(body weight >75 kg) daily
48
Peginteferon-α-2b, 1.5 µg/kg weekly 800 mg (body weight <65 kg); 1000 mg
(body weight 65 to 85 kg); 1200 mg
(body weight >85 to 100 kg); 1400 mg
(body weight >105 but <125 kg
2, 3 Peginteferon-α-2a, 180 µg weekly 800 mg daily 24
Peginteferon-α-2b, 1.5 µg/kg weekly 800 mg daily
Table 2 Extended therapy for slow responders to combination therapy
Study Year Patients, N Treatment SVR after 48 weeks
of treatment
SVR after 72 weeks
of treatment
P-value
Berg et al. [19••] 2006 455 Peginterferon-α-2a, 180 µg/wk,




2006 326 Peginterferon-α-2a, 180 µg/wk,
and ribavirin, 800 mg/day
32% 45% 0.01
Pearlman et al. [18••] 2007 101 Peginterferon-α-2b, 1.5 µg/kg/wk,
and ribavirin, 800–1400 mg/day
18% 38% 0.026
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study found that in the high-dose interferon group, HCV
RNA became undetectable faster and in more patients than
the low interferon group [32]. In a more recent study by
Roberts et al. [33], 896 genotype 1 patients were randomly
assigned 1:1 to a 12-week induction therapy with high-
dose peginterferon-α-2a (360 µg/week) and 36 weeks of
standard peginterferon-α-2a (180 µg/week) or 48 weeks of
standard peginterferon-α-2a. SVR rates were similar in the
induction and control groups (53% vs 50%, P=0.29).
Similarly, in a large multicenter, randomized, open-label
trial involving treatment naïve patients with genotypes 1
and 4 were either treated with induction peginterferon-α-2b
(3.0 µg/kg/wk) for 12 weeks followed by standard dose of
peginterferon-2b-α (1.5 µg/kg/wk) or standard dose of
peginterferon-2b-α for 48 weeks. Both groups were treated
with weight-based ribavirin. Overall, the SVR was 32% in the
induction group versus 29% in the standard peginterferon
dosing group, but the P-value was not significant [34].
Likewise, the PROGRESS trial was unable to find a difference
between patients treated with induction doses of peginterferon-
α-2a (360 µg/wk) for 12 weeks followed by standard dose
peginterferon-α-2a (180 µg/wk) for 36 weeks compared to
standard dose peginterferon-α-2a for 48 weeks (41% vs 43%,
P-value not reported). Both arms were treated with weight-
based ribavirin. The PROGRESS trial, however, found
that patients weighing ≥95 kg and those with nonalcoholic
fatty liver disease activity score ≥3 tended to have higher
rates of SVR when treated with induction doses [35].
Treatment with High-dose Ribavirin
In a small prospective trial of 10 genotype 1 patients with
high HCV viral loads (>800,000 IU/ml), the patients were
treated with ribavirin doses to achieve a steady-state
concentration of >15 µmol/L in addition to standard
peginterferon-α-2a for 48 weeks. The mean dose of
ribavirin was 2540 mg/d (range 1600–3600). The study
found that 90% of patients achieved SVR, but two patients
required blood transfusions and all patients in the study
received erythropoietin for anemia (hemoglobin <8 g/dL),
highlighting safety concerns associated with higher dosing
of ribavirin [36]. In another trial by Shiffman et al. [37],
150 treatment-naïve genotype 1 patients treated with
standard dose of peginterferon-α 2b, high-dose ribavirin
(1000–1600 mg/d), and erythropoietin were found to have
higher rates of SVR compared to patients treated with
regimens containing lower doses of ribavirin (800–
1400 mg/day) (49% vs 29%, P<0.05). Thus, it would
appear that using higher doses of ribavirin than standard
leads to higher rates of SVR when combined with standard
dose peginterferon, but these patients will require regular
screening for anemia and subsequent treatment via transfu-
sion or erythropoiesis-stimulating agents [37].
Treatment of Nonresponders and Relapsers
About 30% of patients with CHC infection do not respond
to peginterferon and ribavirin [29•, 38•]. In a recent study,
only 10% of patients who were initially treated with
peginterferon-α-2b (1.5 µg/kg) and standard dose ribavirin
and did not respond to treatment, achieved SVR when
retreated with peginterferon-α-2a (180 µg/wk) and ribavirin
(1000 mg/d) [39]. Another study by Jensen et al. [40] found
that by re-treating nonresponders with high-dose
peginterferon-α-2a (360 µg/wk) for 12 weeks followed by
standard dose peginterferon-α-2a to complete a 72-week
course had similar SVR rates to re-treatment with
peginterferon-α 2a (180 µg/wk) for 72 weeks (16% vs
14%), which was higher than groups treated for only
48 weeks (7% and 9%). All regimens included combination
therapy with ribavirin. It appears then that switching the
type of interferon has little effect on achieving SVR, but
increasing re-treatment duration to 72 weeks may provide
modest benefit. A more recent multinational study demon-
strated the decision to re-treat requires consideration of
degree of liver damage, genotype, and prior response to
antiviral therapy [41].
The DIRECT (Daily-Dose Consensus Interferon and
Ribavirin: Efficacy of Combined Therapy) trial treated 487
patients who did not respond to treatment with standard
peginterferon and ribavirin were re-treated with consensus
interferon and ribavirin [42]. The SVR rate using 15 µg/d
consensus interferon and ribavirin was 10.7%. Efficacy of
re-treatment was associated with severity of liver damage
and degree of viral response to prior therapy. For instance,
the SVR in patients with at least a 2-log drop in viral levels
with prior pegylated interferon and ribavirin and who did
not have cirrhosis was greater than 30%.
Management of Adverse Reactions
Adverse effects can lead to dose reduction and even
treatment discontinuation. According to the initial trials by
Fried et al. [29•] and Manns et al. [38•], adverse reactions
led to the discontinuation of therapy in 10% to 14% of
patients. The most common adverse reactions reported in
these studies were fatigue, headache, fevers, myalgias, and
injection site reactions. Major reasons for discontinuation of
treatment were severe anemia, neutropenia, thrombo-
cytopenia, and psychiatric disturbances. In the study by
Manns et al. [38•], dose reduction of combination therapy
for neutropenia, anemia, and thrombocytopenia, occurred in
18%, 13%, and 3%, respectively. However, discontinuation
of combination therapy for neutropenia was less than 1%,
no patients discontinued therapy for thrombocytopenia, and
discontinuation for anemia was rare. Although dose
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reduction appears to be the mainstay of adverse reaction
management at this time, the use of growth factors is
currently under investigation and is discussed here.
Hemolytic anemia is one of the limitations of using
ribavirin. Anemia occurs between 15% to 20% of treated
individuals and can lead to dose reduction or even
discontinuation. Consequently, SVR can be decreased [43,
44]. Indeed, the minimal critical dose of ribavirin before
SVR is compromised is likely between 60% and 80% of the
expected dose [45]. In a study by Bronowicki et al. [46],
516 genotype 1 patients were treated with peginterferon-α-
2a (180 µg/wk) plus ribavirin (800 mg/d). Those patients
who achieved an undetectable HCV viral 2load at week 24
(70% of the original 516 patients) were randomized to
either continuing ribavirin or receiving peginterferon
monotherapy for the remaining 24 weeks. The study found
that patients who stopped ribavirin had lower rates of SVR
(52.8% vs 68.2%, P=0.004), but higher quality of life
scores. Hence, ensuring the complete treatment course of
ribavirin is critical to the achievement of SVR [46].
Efforts to maintain ribavirin without dose modification
despite anemia have included the use of erythropoietin.
However, small-scale studies have failed to demonstrate
that the use of erythropoietin to maintain ribavirin dose
translates to better SVR [37, 47, 48]. A concern with these
trials is that they are underpowered to detect a difference, if
one existed. Treatment of anemia with epoetin-α has been
shown to increase patients’ quality of life [49, 50]. In
addition, there has been increased scrutiny regarding the
use of epoetin-α for ribavirin-induced anemia because of
concerns of increased mortality, thrombosis, cardiovascular
events (according to the Food and Drug Administration),
and the rare observation of antibody-mediated pure red cell
aplasia [51]. The Food and Drug Administration has
recommended against the use of epoetin-α in patients with
hemoglobin above 10 g/dL [52].
The role of granulocyte colony-stimulating factors (G-CSF)
in the management of neutropenia induced by combination
therapy has not been established. In a recent retrospective,
cross-sectional study, Koskinas et al. [53] found that HCV
patients who were given G-CSF while undergoing combina-
tion therapy had higher rates of SVR (32% vs 21%), but this
result was not statistically significant. Interestingly, the
authors of this study found that members of the G-CSF
group had higher rates of treatment adherence (95% vs
73.1%, P<0.05). Infection was not listed as a major adverse
reaction in the original trials [28, 33] despite not being treated
with G-CSF; therefore, with the current evidence, routine use
of G-CSF for the treatment of neutropenia induced by
combination therapy is not recommended.
In a recent study by McHutchison et al. [54], 72 patients
with HCV-related cirrhosis and thrombocytopenia (platelet
counts 20,000 to 70,000/cm3) were randomly assigned to
either receive eltrombopag, an orally active thrombopoietin-
receptor agonist that stimulates thrombopoiesis, or placebo
each day for 4 weeks. In this study, 95% of patients reached
the goal of 100,000 platelets at the end of treatment and were
able to initiate antiviral therapy for HCV [54]. The use of
eltrombopag for the treatment of thrombocytopenia caused
by peginterferon and ribavirin is yet to be studied, but may
represent a novel approach to this adverse effect.
Major depression affects about one third of patients being
treated for HCV, and is primarily caused or exacerbated by the
interferon component of combination therapy. A recent
systematic review analyzed interferon-α-induced major de-
pressive disorder [55]. The study found that prophylactic
treatment of patients with a history of depression using
selective serotonin reuptake inhibitors (SSRIs) led to de-
creased rates of treatment discontinuation. For patients who
become depressed while undergoing combination therapy, the
SSRIs appear safe and efficacious, though evidence is limited
at this time. Consultation with mental health professionals
and use of a multidisciplinary team is advised for patients
undergoing combination therapy who have a history of
depression or have become depressed during treatment.
Investigative Therapies
Current response rates appear to be improved with the
addition of protease inhibitors to pegylated interferon and
ribavirin. For instance, in genotype 1 patients, the addition
of telaprevir has been associated with an increase of SVR
from 46% in patients treated with peginterferon and
ribavirin for 48 weeks of treatment, to 69% in patients
treated with telaprevir for 12 weeks then peginterferon and
ribavirin for 24 additional weeks for 36 weeks of total
treatment (P=0.004) [56]. However, this study also showed
that these protease inhibitors have their own set of signature
adverse effects, and are associated with greater rates of
discontinuation (21% vs 11%). Use of a different protease
inhibitor, boceprevir, with peginterferon and ribavirin was
also associated with greater SVR than using peginterferon
and ribavirin alone (74% vs 38%, respectively) [57]. The
signature adverse effect associated with telaprevir appears
to be a skin rash, and with boceprevir anemia. Treatment
duration for both drugs is currently under investigation, but
regimens containing boceprevir appear to range from
24 weeks to 48 weeks at present.
Conclusions
For now, the mainstay of treatment for CHC virus infection
is peginterferon-α and ribavirin. Genotypes 2 and 3 are the
most responsive to therapy and a 24-week course is
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sufficient, whereas a 48-week course is recommended for
genotypes 1 and 4. Currently, too little evidence exists to
recommend treatment regiments for genotypes 5 and 6.
Evidence exists to support treatment with combination
therapy using weight-based ribavirin for as short as
12 weeks for patients with genotypes 2 and 3, but may
need to be extended to 72 weeks for genotype 1 patients
who are slower to respond to therapy.
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